

CURRICULUM VITAE
Glenn Eric Palomaki, PhD

Department of Pathology and Laboratory Medicine
Division of Medical Screening and Special Testing
Women and Infants Hospital of Rhode Island

Primary Business Address: 35 Main Street, Unit 1, Windham, ME 04062
Business Telephone Number: 207-894-6610
Business Fax Number: 207-892-8620
Electronic Mail Address: gpalomaki@ipmms.org

EDUCATION

Undergraduate	University of New Hampshire, Physics, B.S., 1973 University of Southern Maine, Computer Science, B.A., 1981
Graduate	Queen Mary University of London, Environmental and Preventive Medicine, PhD, April, 2011

ACADEMIC APPOINTMENTS

1979-1981	Teaching Assistant in Physics, Bowdoin College, Brunswick, ME 04011
1973-1978	Physics/Math/Biology, Winthrop High School, Winthrop, ME 04364
1978	Physics/Math Teacher, International School Nido de Aguilas, Santiago 9, Chile
1990-2004	Adjunct Instructor, Dept. of Applied Medical Sciences, University of South- ern Maine, Portland, ME
2005-2011	Senior Research Associate in Pathology and Laboratory Medicine
2012-present	Associate Professor (Research), Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI

OTHER APPOINTMENTS

1981-1988	Biostatistician/Senior Systems Analyst, Foundation for Blood Research, Scarborough, Maine
1988-2005	Director of Biometry/Epidemiology, Foundation for Blood Research, Scar- borough, Maine
1991-Present	Member, Editorial Board, Journal of Medical Screening
2005-Present	Associate Director, Division of Medical Screening and Special Testing, De- partment of Pathology & Laboratory Medicine, Women & Infants Hospital, Providence, Rhode Island

MEMBERSHIP IN SOCIETIES

1987-Present	Member, New England Regional Genetics Group
1992-2005	Consultant, Therapeutic Drug Monitoring/Endocrine Resource Committee, College of American Pathologists
1996-Present	Member, American College of Medical Genetics
1997-Present	Co-Chair, Data Committee, New England Regional Genetics Group
1997-Present	Member, Subcommittee on AFP and Related Analytes, American College of Medical Genetics
1998-2000	Co-Director, New England Regional Genetics Group

2001-Present	Member, Quality Assurance Committee, American College of Medical Genetics
2010-Present	Consultant, Biochemical and Molecular Genetics Resource Committee, College of American Pathologists
2011-Present	Member, Evidence Evaluation Methods Workgroup, Health Resources and Health Services Administration (HRSA), US Department of Health and Human Services
2010-Present	Member, Ad Hoc Committee on the Value of Genetic Diagnosis, American College of Medical Genetics

ORIGINAL PUBLICATIONS IN PEER REVIEWED JOURNALS

1. Mahoney RJ, Gazit E, MacCarthy-Shanley K, Martin-Alosco S, **Palomaki GE**, Smith DE, Yunis EJ: Alloantisera detect HLA-A-B-C and non-HLA differentiation antigens on human thymocytes. *J Immunol*, 129:2630-2635, 1982.
2. Haddow JE, Knight GJ, **Palomaki GE**: Does smoking influence serum alpha-fetoprotein levels in mid-trimester pregnancies. *Br J Obstet Gynaecol*, 91:1188-1191, 1984.
3. Keilson J, Lambert D, Fabian D, Theborge J, Ackerson T, **Palomaki GE**, Turgeon W: Screening for hypothermia in the ambulatory elderly - The Maine Experience. *JAMA*, 254:1781-1784, 1984.
4. Collaborative Report - Is there a future for lower-tar-yield cigarettes? Fourth Scarborough Conference on Preventive Medicine. *Lancet*, ii:1111-1114, 1985.
5. Haddow JE, Knight GJ, Kloza EM, **Palomaki GE**: Alpha-fetoprotein, vaginal bleeding, and pregnancy risk. *Br J Obstet Gynaecol*, 93:589-593, 1986.
6. Knight GJ, **Palomaki GE**, Haddow JE: Assessing reliability of AFP test kits. *Contemp OB/GYN*, 30:37-52, 1987.
7. Knight GJ, Haddow JE, **Palomaki GE**, Haddow JE: Selection and validation of alpha-fetoprotein assay kits for the screening of Down syndrome. *Am J Obstet Gynecol*, 156:1557-1559, 1987.
8. **Palomaki GE**, Haddow JE: Maternal serum alpha-fetoprotein, age, and Down syndrome risk. *Am J Obstet Gynecol*, 156:460-463, 1987.
9. Haddow JE, **Palomaki GE**, Knight GJ: Can low birth weight after elevated maternal serum alpha-fetoprotein be explained by maternal weight? *Obstet Gynecol*, 70:26-28, 1987.
10. Haddow JE, Knight GJ, **Palomaki GE**, Kloza EM, Wald NJ: Cigarette consumption and serum cotinine in relation to birthweight. *Br J Obstet Gynaecol*, 94:678-681, 1987.
11. Haddow JE, Hill LE, **Palomaki GE**, Knight GJ: Very low versus undetectable maternal serum alpha-fetoprotein values and fetal death. *Prenat Diagn*, 7:401-406, 1987.
12. Knight GJ, **Palomaki GE**, Haddow JE: Use of maternal serum alpha-fetoprotein measurements to screen for Down's syndrome. *Clin Obstet Gynecol*, 31:306-327, 1988.
13. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, Knight GJ, **Palomaki GE**: Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. *Br J Obstet Gynaecol*, 95:334-341, 1988.
14. Canick JA, Knight GJ, **Palomaki GE**, Haddow JE, Cuckle HS, Wald NJ: Low second trimester maternal serum unconjugated oestriol in pregnancies with Down syndrome. *Br J Obstet Gynaecol*, 95:330-333, 1988.
15. **Palomaki GE**, Hill LE, Knight GJ, Haddow JE, Carpenter M: Second-trimester maternal serum alpha-fetoprotein levels in pregnancies associated with gastroschisis and omphalocele. *Obstet Gynecol*, 71:906-909, 1988.
16. Haddow JE, Knight GJ, **Palomaki GE**, McCarthy JE: Second-trimester serum cotinine levels in non-smokers in relation to birth weight. *Am J Obstet Gynecol*, 159:481-484, 1988.
17. Wald NJ, Cuckle HS, Densem J, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, **Palomaki GE**, Canick J: Maternal serum screening for Down's syndrome in early pregnancy. *BMJ*, 297:883-887, 1988.

18. Haddow JE, Knight GJ, **Palomaki GE**, Haddow PK: Estimating fetal morbidity and mortality resulting from cigarette smoke exposure by measuring cotinine levels in maternal serum. *Prog Clin Biol Res*, 281:289-300, 1988.
19. Goldfine C, Knight GJ, Haddow JE, **Palomaki GE**: Amniotic fluid acetylcholinesterase measurements: comparing immunochemical and polyacrylamide gel techniques. *Prenat Diagn*, 9:167-172, 1989.
20. Haddow JE, Knight GJ, **Palomaki GE**, McCarthy JE, Foss KC: Serum cotinine levels in pregnant non-smokers in relation to birthweight. *Ann NY Acad Sci*, 562:370-371, 1989.
21. Wald NJ, Cuckle HS, Sneddon J, Haddow JE, **Palomaki GE**: Screening for Down's syndrome. *Am J Hum Genet*, 44:586-587, 1989.
22. Craig WY, **Palomaki GE**, Haddow JE: Cigarette smoking and serum lipid and lipoprotein levels: an analysis of published data. *BMJ*, 298:784-788, 1989.
23. **Palomaki GE**, Williams J, Haddow JE: Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. An eight center prospective collaborative study. *Am J Obstet Gynecol*, 160:575-581, 1989.
24. Goldfine C, Haddow JE, Knight GJ, **Palomaki GE**: Amniotic fluid alpha-fetoprotein and acetylcholinesterase measurements in pregnancies associated with gastroschisis. *Prenat Diagn*, 9:697-700, 1989.
25. Knight GJ, **Palomaki GE**, Lea DH, Haddow JE: Exposure to environmental tobacco smoke measured by cotinine ¹²⁵I-radioimmunoassay. *Clin Chem*, 35:1036-1039, 1989.
26. Craig WY, **Palomaki GE**, Johnson AM, Haddow JE: Cigarette smoking-associated changes in blood lipid and lipoprotein levels in the 8- to 19-year-old age group: a meta-analysis. *Pediatrics*, 85:155-158, 1990.
27. Knight GJ, **Palomaki GE**: Maternal serum alpha-fetoprotein screening for fetal Down syndrome. *J Clin Immunoassay*, 13:23-29, 1990.
28. **Palomaki GE**, Knight GJ, Holman MS, Haddow JE: Maternal serum alpha-fetoprotein screening for fetal Down syndrome in the United States: Results of a survey. *Am J Obstet Gynecol*, 162:317-321, 1990.
29. Johnson AM, **Palomaki GE**, Haddow JE: Maternal serum alpha-fetoprotein levels in pregnancies among black and white women with fetal open spina bifida: a United States collaborative study. *Am J Obstet Gynecol*, 162:328-331, 1990.
30. Johnson AM, **Palomaki GE**, Haddow JE: The effect of adjusting maternal serum alpha-fetoprotein levels for maternal weight in pregnancies with fetal open spina bifida. A United States collaborative study. *Am J Obstet Gynecol*, 163:9-11, 1990.
31. Chilmonczyk BA, Knight GJ, **Palomaki GE**, Pulkkinen AJ, Williams J, Haddow JE: Environmental tobacco smoke exposure during infancy. *Am J Public Health*, 80:1205-1208, 1990.
32. Canick JA, Knight GJ, **Palomaki GE**, Haddow JE: Second-trimester levels of maternal serum unconjugated oestriol and human chorionic gonadotropin in pregnancies affected by fetal anencephaly and open spina bifida. *Prenat Diagn*, 10:733-737, 1990.
33. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, **Palomaki GE**, Hitchcox SA, White BW, Himmelfarb J, Leeber DA: The flow cytometric crossmatch and early renal transplant loss. *Transplantation*, 49:527-535, 1990.
34. Haddow JE, Knight GJ, Kloza EM, **Palomaki GE**, Wald NJ: Cotinine-assisted intervention in pregnancy to reduce smoking and low birthweight delivery. *Br J Obstet Gynaecol*, 98:859-865, 1991.
35. Rose NC, Haddow JE, **Palomaki GE**, Knight GJ: Self-rated physical activity level during the second trimester and pregnancy outcome. *Obstet Gynecol*, 78:1078-1080, 1991.
36. Haddow JE, Rote NS, Dostal-Johnson D, **Palomaki GE**, Pulkkinen AJ, Knight GJ: Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester. *Am J Obstet Gynecol*, 165:1308-1312, 1991.
37. Chilmonczyk BA, **Palomaki GE**, Knight GJ, Williams J, Haddow JE: An unsuccessful cotinine-assisted intervention strategy to reduce environmental tobacco smoke exposure during infancy. *Am J Dis Child*, 146:357-360, 1992.

38. Haddow JE, **Palomaki GE**, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Bowers GB: Prenatal screening for Down's syndrome with use of maternal serum markers. *N Engl J Med*, 327:588-593, 1992.
39. **Palomaki GE**, Knight GJ, Haddow JE, Canick JA, Saller DN, Panizza DS: Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. *Prenat Diagn*, 12:925-930, 1992.
40. Willhoite MB, Bennert HW, **Palomaki GE**, Zarella MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. The experience of the Maine Diabetes in Pregnancy Program. *Diabetes Care*, 16:450-455, 1993.
41. Wald NJ, Hackshaw A, Haddow JE, **Palomaki GE**, Knight GJ: Use of free beta-hCG in Down's syndrome. *Ann Clin Biochem*, 30:512-518, 1993.
42. Haddow JE, **Palomaki GE**, Holman MS: Young maternal age and smoking during pregnancy as risk factors for gastroschisis. *Teratology*, 47:225-228, 1993.
43. **Palomaki GE**, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A: Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin: Impact on Down syndrome screening. *Obstet Gynecol*, 81:675-678, 1993.
44. Wald NJ, Smith D, Kennard A, **Palomaki GE**, Salonen R, Holzgreve W, Pejtsik B, Coombes EJ, Mancini G, MacRae AR, Wyatt P, Roberson J: Biparietal diameter and crown-rump length in fetuses with Down's syndrome: implications for antenatal serum screening for Down's syndrome. *Br J Obstet Gynaecol*, 100:430-435, 1993.
45. Chilmonczyk BA, Salmun LL, Megathlin KN, Neveux L, **Palomaki GE**, Knight GJ, Pulkkinen AJ, Haddow JE: Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. *N Engl J Med*, 328:1665-1669, 1993.
46. **Palomaki GE**, Knight GJ, McCarthy JE, Haddow JE, Eckfeldt JH: Maternal serum screening for fetal Down syndrome in the United States: A 1992 survey. *Am J Obstet Gynecol*, 169:1558-1562, 1993.
47. Ledue TB, Neveux LM, **Palomaki GE**, Ritchie RF, Craig WY: The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. *Clin Chim Acta*, 223:73-82, 1993.
48. **Palomaki GE**, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A: Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening. *Obstet Gynecol*, 81:675-678, 1993.
49. **Palomaki GE**: Population based prenatal screening for the fragile X syndrome. *J Med Screen*, 1:65-72, 1994.
50. Haddow JE, Knight GJ, **Palomaki GE**, Neveux LM, Chilmonczyk BA: Replacing creatinine measurements with specific gravity values to adjust urine cotinine concentrations. *Clin Chem*, 40:562-564, 1994.
51. Rose NC, **Palomaki GE**, Haddow JE, Goodman DBP, Mennuti MT: Maternal serum alpha-fetoprotein screening for chromosomal abnormalities: a prospective study in women aged 35 and older. *Am J Obstet Gynecol*, 170:1073-1078; discussion 1078-1080, 1994.
52. Saller DN, Canick JA, **Palomaki GE**, Knight GJ, Haddow JE: Second-trimester maternal serum alpha-fetoprotein, unconjugated estriol and hCG levels in pregnancies with ventral wall defects. *Obstet Gynecol*, 84:852-855, 1994.
53. Rose NC, Canick JA, Knight GJ, Pulkkinen AJ, Tumber MB, Mennuti MT, **Palomaki GE**: Second trimester diurnal variation of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol: is it present and does it affect the prediction of a patient's risk for fetal Down syndrome? *Prenat Diagn*, 14:947-951, 1994.
54. Haddow JE, **Palomaki GE**, Knight GJ, Cunningham GC, Lustig LS, Boyd PA: Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. *N Engl J Med*, 330:1114-1118, 1994.
55. Donnenfeld AE, Carlson DE, **Palomaki GE**, Librizzi RJ, Weiner S, Platt LD: Prospective multicenter study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies. *Am J Obstet Gynecol*, 84:844-847, 1994.

56. Johnson AM, Ledue TB, **Palomaki GE**, Craig WY: Effect of storage at -70 degrees-C on immunoturbidimetric assays for apolipoproteins A-1 and B. *Clin Chim Acta*, 231:89-94, 1994.
57. **Palomaki GE**, Knight GJ, Haddow JE: Human chorionic gonadotropin and unconjugated oestriol measurements in insulin dependent diabetic pregnant women being screened for fetal Down syndrome. *Prenat Diagn*, 14:65-68, 1994.
58. **Palomaki GE**, Williams J, Haddow JE, Natowicz MR: Tay-Sachs disease in persons of French-Canadian heritage in northern New England. *Am J Med Genet*, 56:409-412, 1995.
59. Haddow JE, **Palomaki GE**, Knight GJ: Effect of parity on human chorionic gonadotrophin levels and Down's syndrome screening. *J Med Screen*, 2:28-30, 1995.
60. Craig WY, Poulin SE, **Palomaki GE**, Neveux LM, Ritchie RF, Ledue TB: Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. *Arterioscler Thromb Vasc Biol*, 15:733-739, 1995.
61. **Palomaki GE**, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA, Saller DN, Blitzer MG, Dickerman LH: Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. *Prenat Diagn*, 15:713-723, 1995.
62. Canick JA, Kellner LH, Saller DN, **Palomaki GE**, Walker RP, Osanthanonndh R: Second-trimester levels of maternal urinary gonadotropin peptide in Down syndrome pregnancy. *Prenat Diagn*, 15:739-744, 1995.
63. Craig WY, Poulin SE, Neveux LM, **Palomaki GE**, Dostal-Johnson DA, Ledue TB, Ritchie RF: Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipo-protein- and oxidation-related analytes. *J Autoimmun*, 8:713-726, 1995.
64. Simpson JL, **Palomaki GE**, Mercer B, Haddow JE, Andersen R, Sibai B, Elias S: Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. *Am J Obstet Gynecol*, 173:1742-1748, 1995.
65. Neveux LM, **Palomaki GE**, Knight GJ, Haddow JE: Multiple marker screening for Down syndrome in twin pregnancies. *Prenat Diagn*, 16:29-34, 1996.
66. **Palomaki GE**, Neveux LM, Haddow JE: Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials? *J Med Screen*, 3:12-17, 1996.
67. Doherty RA, **Palomaki GE**, Kloza EM, Erickson JL, Haddow JE: Couple-based prenatal screening for cystic fibrosis in primary care settings. *Prenat Diagn*, 16:397-404, 1996.
68. **Palomaki GE**, Haddow JE: Gestational dating on the calculation of patient specific risks in Down syndrome. *Ann Clin Biochem*, 33:359-361, 1996.
69. Neveux LM, **Palomaki GE**, Larrivee DA, Knight GJ, Haddow JE: Refinements in managing maternal weight adjustment for interpreting prenatal screening results. *Prenat Diagn*, 16:1115-1119, 1996.
70. Lambert-Messerlian GM, Canick JA, **Palomaki GE**, Schneyer AL: Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. *J Med Screen*, 3:58-62, 1996.
71. **Palomaki GE**: Down's syndrome epidemiology and risk estimation. *Early Hum Dev*, 47(Suppl):S19-S26, 1996.
72. Bradley LA, Haddow JE, **Palomaki GE**: Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands. *J Med Screen*, 3:171-177, 1996.
73. Bradley LA, Haddow JE, **Palomaki GE**: Population screening for haemochromatosis: a unifying analysis of published intervention trials. *J Med Screen*, 3:178-184, 1996.
74. Star J, Canick JA, **Palomaki GE**, Carpenter MW, Saller DN, Sung CJ, Tumber MB, Coustan DR: The relationship between second-trimester amniotic fluid insulin and glucose levels and subsequent gestational diabetes. *Prenat Diagn*, 17:149-154, 1997.
75. Isozaki T, **Palomaki GE**, Bahado-Singh RO, Cole LA: Screening for Down syndrome pregnancy using beta-core fragment: prospective study. *Prenat Diagn*, 17:407-413, 1997.
76. **Palomaki GE**, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM: Maternal serum screening for Down syndrome in the United States: A 1995 survey. *Am J Obstet Gynecol*, 176:1046-1051, 1997.

77. Bradley LA, Canick JA, **Palomaki GE**, Haddow JE: Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. *Am J Obstet Gynecol*, 176:531-535, 1997.
78. Cole LA, Kellner LH, Isozaki T, **Palomaki GE**, Iles RK, Walker RP, Ozaki M, Canick JA: Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies. *Prenat Diagn*, 17:607-614, 1997.
79. Cole LA, Jacobs M, Isozaki T, **Palomaki GE**, Bahado-Singh RO, Mahoney MJ: Screening for Down syndrome using urine hCG free beta-subunit in the second trimester of pregnancy. *Prenat Diagn*, 17:1107-1112, 1997.
80. Cole LA, Acuna E, Isozaki T, **Palomaki GE**, Bahado-Singh RO, Mahoney MJ: Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies. *Prenat Diagn*, 17:1125-1134, 1997.
81. Kellner LH, Canick JA, **Palomaki GE**, Neveux LM, Saller DN, Walker RP, Osathanondh R, Bombard AT: Levels of urinary beta-core fragment, total oestriol and the ratio of the two in second trimester screening for Down syndrome. *Prenat Diagn*, 17:1135-1141, 1997.
82. Haddow JE, **Palomaki GE**, Knight GJ, Williams J, Miller WA, Johnson A: Screening of maternal serum for fetal Down's syndrome in the first trimester. *N Engl J Med*, 338:955-961, 1998.
83. Knight GJ, **Palomaki GE**, Neveux LM, Fodor KK, Haddow JE: hCG and the free beta-subunit as screening tests for Down syndrome. *Prenat Diagn*, 18:235-245, 1998.
84. Bradley LA, Johnson DD, **Palomaki GE**, Haddow JE, Roberson NH, Ferrie RM: Hereditary h emochromatosis mutation frequencies in the general population. *J Med Screen*, 5:34-36, 1998.
85. Craig WY, Neveux LM, **Palomaki GE**, Cleveland MM, Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: meta analysis of prospective trials. *Clin Chem*, 44:2301-2306, 1998.
86. Haddow JE, **Palomaki GE**, Knight GJ, Foster DL, Neveux LM: Second trimester screening for Down's syndrome using maternal serum dimeric inhibin-A. *J Med Screen*, 5:115-119, 1998.
87. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for immunoglobulins A, G and M: a practical, simple and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 12:363-370, 1998.
88. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O: Reference distributions for Immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 12:371-377, 1998.
89. Haddow JE, **Palomaki GE**, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ: Maternal thyroid deficiency during pregnancy and subsequent psychological development of the child. *N Engl J Med*, 341:549-555, 1999.
90. Bradley LA, **Palomaki GE**, Knight GJ, Haddow JE, Opitz JM, Irons M, Kelley RI, Tint GS: Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. *Am J Med Genet*, 82:355-358, 1999.
91. Haddow JE, Bradley LA, **Palomaki GE**, Doherty RA, Bernhardt BA, Brock DJH, et al. Issues in implementing prenatal screening for cystic fibrosis: results of a working conference. *Genet Med*, 1:129-135, 1999.
92. Haddow JE, Bradley LA, **Palomaki GE**, Doherty RA. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. *J Med Screen*, 6:60-66, 1999.
93. Saller DN, Canick JA, Blitzler MG, **Palomaki GE**, Schwartz S, Blakemore KJ, Haddow JE: Second-trimester maternal serum analyte levels associated with fetal trisomy 13. *Prenat Diagn*, 19:813-816, 1999.
94. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O: Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. *J Clin Lab Anal*, 13:280-286, 1999.
95. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a practical, simple, and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 13:273-279, 1999.

96. Allan WC, Haddow JE, **Palomaki GE**, Williams JR, Mitchell ML, Hermos RJ, Faix JD: Maternal thyroid deficiency and pregnancy complications: implications for population screening. *J Med Screen*, 7:127-130, 2000.
97. Lambert-Messerlian GM, **Palomaki GE**, Canick JA: Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects. *Prenat Diagn*, 20:680-682, 2000.
98. Mitchell ML, Hermos RJ, Larson CA, **Palomaki GE**, Haddow JE: Prevalence of GAD autoantibodies in women with gestational diabetes: a retrospective analysis. *Diabetes Care*, 23:1705-1706, 2000.
99. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the positive acute phase serum proteins alpha-1-acid glycoprotein (orosomuroid), alpha-1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 14:284-292, 2000.
100. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the positive acute phase serum proteins alpha-1-acid glycoprotein (orosomuroid), alpha-1-antitrypsin, and haptoglobin: a comparison of a large cohort to the world's literature. *J Clin Lab Anal*, 14:265-270, 2000.
101. Steele BW, Wang E, **Palomaki GE**, Klee GG, Elin RJ, Witte DL: Sources of variability: A College of American Pathologists Therapeutic Drug Monitoring Survey Study. *Arch Path Lab Med*, 125:183-190, 2001.
102. Allan WC, Timothy K, Vincent GM, **Palomaki GE**, Neveux LM, Haddow JE: Long QT syndrome in children: the value of rate corrected QT interval in children who present with fainting. *J Med Screen*, 8:178-182, 2001.
103. Allan WC, Timothy K, Vincent GM, **Palomaki GE**, Neveux LM, Haddow JE: Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. *J Med Screen*, 8:173-177, 2001.
104. Knight GJ, **Palomaki GE**, Neveux LM, Haddow JE, Lambert-Messerlian GM: Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. *J Med Screen*, 8:2-7, 2001.
105. **Palomaki GE**, Neveux LM: Using multiples of the median to normalize serum protein measurements. *Clin Chem Lab Med*, 39:1137-1145, 2001.
106. Steele BW, Wang E, **Palomaki GE**, Klee GG, Elin RJ, Soldin SJ, Witte DL: An evaluation of analytic goals for assays of drugs. A College of American Pathologists Therapeutic Drug Monitoring Survey Study. *Arch Pathol Lab Med*, 125:729-735, 2001.
107. **Palomaki GE**, Bradley LA, Knight GJ, Craig WY, Haddow JE: Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. *J Med Screen*, 9:43-44, 2002.
108. **Palomaki GE**, Haddow JE, Bradley LA, FitzSimmons SC: An updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. *Genet Med*, 4:90-94, 2002.
109. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow JE, Lau J, **Palomaki GE**, Press N, Richards CS, Wideroff L, Wiesner GL: Genetic test evaluation: Information needs of clinicians, policy-makers, and the public. *Am J Epidemiol*, 311-318, 2002.
110. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for serum iron and transferrin saturation: a comparison of a large cohort to the world's literature. *J Clin Lab Anal*, 16: 246-252, 2002.
111. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for serum iron and transferrin saturation: a practical, simple, and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 16:237-245, 2002.
112. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, McGinnis MJ, Prior TW, Popovich BW, Watson MS, **Palomaki GE**: Standards and guidelines for CFTR mutation testing. *Genet Med*, 4:379-391, 2002.
113. **Palomaki GE**, Bradley LA, Richards CS, Haddow JE: Analytic validity of cystic fibrosis testing: a preliminary estimate. *Genet Med*, 5:15-20, 2003.
114. **Palomaki GE**, Neveux LM, Knight GJ, Haddow JE: Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. *Prenat Diagn*, 23:243-247, 2003.

115. Farina A, LeShane ES, Lambert-Messerlian GM, Canick JA, Lee T, Neveux LM, **Palomaki GE**, Bianchi DW: Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. *Clin Chem*, 49:239-242, 2003.
116. Haddow JE, **Palomaki GE**, McClain M, Craig W: Hereditary hemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. *J Med Screen*, 10:11-13, 2003.
117. Wald NJ, Morris JK, Rodeck CH, Haddow JE, **Palomaki GE**: Cystic fibrosis: selecting the prenatal screening strategy of choice. *Prenat Diagn*, 23:474-483, 2003.
118. **Palomaki GE**, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW: Estimated analytic validity of *HFE* C282Y mutation testing in population: the potential value of confirmatory testing. *Genet Med*, 5:440-443, 2003.
119. Knight GJ, **Palomaki GE**: Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome. *Clin Lab Med*, 23:531-551, 2003.
120. **Palomaki GE**, Knight GJ, Roberson MM, Cunningham GC, Lee JE, Strom CM, Pandian R: Invasive trophoblastic antigen (hyperglycosylated human chorionic gonadotropin) in second-trimester maternal urine as a marker for Down syndrome: preliminary results of an observational study on fresh samples. *Clin Chem*, 50:182-189, 2004.
121. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O: Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature. *J Clin Lab Anal*, 18:9-13, 2004.
122. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TM, Craig WY: Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 18:1-8, 2004.
123. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O, Ledue TM, Craig WY: Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 18:139-152, 2004.
124. Ritchie RF, **Palomaki GE**, Neveux LM, Navolotskaia O: Reference distributions for alpha2-macroglobulin: a comparison of a large cohort to the world's literature. *J Clin Lab Anal*, 18:148-152, 2004.
125. Ritchie RF, **Palomaki GE**: Selecting clinically relevant populations for reference intervals. *Clin Chem Lab Med*, 42:702-709, 2004.
126. Pandian RJ, Cole LA, **Palomaki GE**: Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening. *Clin Chem*, 50:1433-1435, 2004.
127. **Palomaki GE**, FitzSimmons SC, Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via *CFTR* carrier testing in a United States pan-ethnic population. *Genet Med*, 6:405-414, 2004.
128. Watson MS, Cutting GR, Desnik RJ, Driscoll DA, Klinger K, Mennuti M, **Palomaki GE**, Popovich BW, Pratt VM, Rohlf EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. *Genet Med*, 6:387-391, 2004.
129. Haddow JE, Knight GJ, **Palomaki GE**, McClain MR, Pulkkinen AJ: The reference range and within-person variability of thyroid stimulating hormone (TSH) during the first and second trimesters of pregnancy. *J Med Screen*, 11:170-174, 2004.
130. **Palomaki GE**, Neveux LM, Knight GJ, Haddow JE, Pandian R: Maternal serum invasive trophoblast antigen (ITA) as a screening marker for Down syndrome during the second trimester. *Clin Chem*, 50:1804-1808, 2004.
131. Knight GJ, **Palomaki GE**, Klee GG, Schreiber WE, Cole LA: A comparison of human chorionic gonadotropin-related components in fresh frozen serum with the proficiency testing material used by the College of American Pathologists. *Arch Pathol Lab Med*, 129:328-330, 2005.
132. Schreiber WE, Endres DB, McDowell GA, **Palomaki GE**, Elin JR, Klee GG, Wang E: Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists Surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin and prostate-specific antigen. *Arch Pathol Lab Med*, 129:331-337, 2005.

133. McClain MR, Nathanson KL, **Palomaki GE**, Haddow JE: An evaluation of *BRCA1* and *BRCA2* founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. *Genet Med*, 7:34-39, 2005.
134. McClain MR, **Palomaki GE**, Nathanson KL, Haddow JE: Adjusting the estimated proportion of breast cancer cases associated with *BRCA1* and *BRCA2* mutations: public health implications. *Genet Med*, 7:28-33, 2005.
135. Isman F, **Palomaki GE**, Natowicz MR: Lysosomal enzymes in human peripheral blood mononuclear cells and granulocytes. *Clin Chem*, 51:646-649, 2005.
136. **Palomaki GE**, Bradley LA, McDowell GA, Down Syndrome Working Group, ACMG Laboratory Quality Assurance Committee: Technical standards and guidelines: prenatal screening for Down syndrome. *Genet Med*, 7:344-354, 2005.
137. Bradley LA, **Palomaki GE**, McDowell GA, Down Syndrome Working Group, ACMG Laboratory Quality Assurance Committee: Technical standards and guidelines: prenatal screening for open neural tube defects. *Genet Med*, 7:355-369, 2005.
138. Law MR, **Palomaki G**, Alfirevic Z, Gilbert R, Heath P, McCartney C, Reid T, Schrag S: The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. *J Med Screen*, 12:60-68, 2005.
139. Spector EB, Grody WW, Matteson CJ, **Palomaki GE**, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS: Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. *Genet Med*, 7:444-453, 2005.
140. **Palomaki GE**, Knight GJ, Neveux LM, Pandian R, Haddow JE: Maternal serum invasive trophoblast antigen (ITA) and first trimester Down syndrome screening. *Clin Chem*, 51:1499-1504, 2005.
141. **Palomaki GE**, Kloza EM, Haddow JE, Williams J, Knight GJ: Patient and health professional acceptance of integrated serum screening for Down syndrome. *Semin Perinatol*, 29:247-251, 2005.
142. Knight GJ, **Palomaki GE**, Neveux L, Smith DE, Kloza EM, Pulkkinen AJ, Williams J, Haddow JE: Integrated serum screening for Down's syndrome in primary obstetric practice. *Prenat Diagn*, 25:1162-1167, 2005.
143. Lambert-Messerlian GM, Eklund EE, Malone FD, **Palomaki GE**, Canick JA, D'Alton ME: Stability of first- and second-trimester serum markers after storage and shipment. *Prenat Diagn*, 26:17-21, 2006.
144. Haddow JE, McClain MR, **Palomaki GE**, Kloza EM, Williams J: Screening for thyroid disorders during pregnancy: results of a survey in Maine. *Am J Obstet Gynecol*, 194:471-474, 2006.
145. Bdolah Y, **Palomaki GE**, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA: Circulating angiogenic proteins in trisomy 13. *Am J Obstet Gynecol*, 194:239-245, 2006.
146. **Palomaki GE**, Steinort K, Knight GJ, Haddow JE: Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. *Obstet Gynecol*, 107:367-375, 2006.
147. **Palomaki GE**, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE: Screen positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a cohort of 21- to 55-year-old women. *Genet Med*, 8:161-168, 2006.
148. MacRae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, **Palomaki GE**, Yerna M-J, Jaffe AS: Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. *Clin Chem*, 52:812-818, 2006.
149. Kavsak PA, MacRae AR, Lustig V, Bhargava R, Vandersluis R, **Palomaki GE**, Yerna M-J, Jaffe AS: The impact of ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. *Am Heart J*, 152:118-125, 2006.
150. **Palomaki GE**, Wright DE, Summers AM, Neveux LM, Meier C, O'Donnell A, Huang T, Knight GJ, Haddow JE: Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. *Prenat Diagn*, 26:730-739, 2006.

151. Craig WY, Haddow JE, **Palomaki GE**, Kelley RI, Kratz LE, Shackleton CHL, Marcos J, Tint GS, Roberson M, MacRae AR, Nowaczyk MJ, Kloza EM, Irons MB: Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down's syndrome. *Prenat Diagn*, 26:842-849, 2006.
152. Ritchie RF, **Palomaki GE**, Neveux LM, Ledue TM, Craig WY, Marcovina S, Navolotskaia O: Reference distributions for apolipoproteins A1, B, and B/A1 ratios: a practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 20:209-217, 2006.
153. Ritchie RF, **Palomaki GE**, Neveux LM, Ledue TM, Marcovina S, Navolotskaia O: Reference distributions for apolipoproteins A1, B, and B/A1 ratios: comparison of a large cohort to the world's literatures. *J Clin Lab Anal*, 20:218-226, 2006.
154. Kavsak PA, MacRae AR, **Palomaki GE**, Newman AM, Ko DT, Lustig V, Tu JV, Jaffe AS: Health outcomes categorized by current and previous definitions of acute myocardial infarction in an unselected cohort of troponin-naïve emergency department patients. *Clin Chem*, 52:2028-2035, 2006.
155. Canick JA, Lambert-Messerlian G, **Palomaki GE**, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME for the First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium. Comparison of serum markers in first-trimester Down syndrome screening. *Obstet Gynecol*, 108:1192-1199, 2006.
156. **Palomaki GE**, Canick JA, Lambert-Messerlian GM. A summary analysis of Down Syndrome markers in the late first trimester. *Adv Clin Chem*, 43:177-210, 2007.
157. Kavsak PA, Newman AM, Lustig V, MacRae AR, **Palomaki GE**, Ko DT, Tu JV, Jaffe AS: Long-term health outcomes associated with detectable troponin I concentrations. *Clin Chem*, 53:220-227, 2007.
158. Haddow JE, McClain MR, **Palomaki GE**, Hollowell JG: Urine iodine measurements, creatinine adjustment and thyroid deficiency in an adult United States population. *J Clin Endocrinol Metab*, 92:1019-1022, 2007.
159. Craig WY, Haddow JE, **Palomaki GE**, Roberson M: Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz Syndrome (SLOS). *Prenat Diagn*, 27:409-414, 2007.
160. **Palomaki GE**, Neveux LM, Haddow JE, Wyatt P: Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy. *Prenat Diagn*, 27:808-813, 2007.
161. **Palomaki GE**, Neveux LM, Knight GJ, Haddow JE, Lee J: Estimating first trimester combined screening performance for Down syndrome in dried blood spots versus fresh sera. *Genet Med*, 9:458-463, 2007.
162. Gudgeon JM, McClain MR, **Palomaki GE**, Williams MS: Experience with a rapid and structured approach for evaluating gene-based testing. *Genet Med*, 9:473-478, 2007.
163. Shackleton CHL, Marcos J, **Palomaki GE**, Craig WY, Kelley RI, Kratz LE, Haddow JE: Dehydrosteroid measurements in maternal urine or serum for the prenatal diagnosis of Smith-Lemli-Opitz syndrome (SLOS). *Am J Hum Genet Part A*, 143A:2129-2136, 2007.
164. Kavsak PA, Ko DT, Newman AM, **Palomaki GE**, Lustig V, MacRae AR, Jaffe AS: Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-Terminal Pro-Brain Natriuretic Peptide. *Clin Chem*, 53:2112-2118, 2007.
165. McClain MR, **Palomaki GE**, Piper M, Haddow JE: A Rapid ACCE review of *CYP2C9* and *VKORC1* allele testing to inform initial warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. *Genet Med*, 10:89-98, 2008.
166. Kavsak PA, Ko DT, Newman AM, **Palomaki GE**, Lustig V, MacRae AR, Jaffe AS: "Upstream markers" provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. *Clin Chim Acta*, 387:133-138, 2008.
167. Monaghan KG, Feldman GL, **Palomaki GE**, Spector EB; Ashkenazi Jewish Reproductive Screening Working Group; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee: Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. *Genet Med*, 10:57-72, 2008.

168. **Palomaki GE**, Neveux LM, Donnenfeld A, Lee J, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner L, Zebelman A, Haddow JE: Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective, *Genet Med*, 10:131-138, 2008.
169. Kavsak PA, Newman AM, Ko DT, **Palomaki GE**, Lustig V, MacRae AR, Jaffe AS: Is a pattern of increasing biomarker concentrations important for long-term risk stratification in acute coronary syndrome patients presenting early after the onset of symptoms? *Clin Chem*, 54:747-751, 2008.
170. Kavsak PA, Ko DT, Newman AM, Lustig V, **Palomaki GE**, MacRae AR, Jaffe AS: Vascular versus myocardial dysfunction in acute coronary syndrome: Are the adhesion molecules as powerful as NT-proBNP for long-term risk stratification? *Clin Biochem*, 41:436-439, 2008.
171. McClain MR, **Palomaki GE**, Hampel H, Westman JA, Haddow JE: Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. *Fam Cancer*, 7:341-345, 2008.
172. Lambert-Messerlian G, McClain MR, Haddow JE, **Palomaki GE**, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Gross SJ, D'Alton ME: First and second trimester thyroid hormone reference data in pregnant women: a FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *Am J Obstet Gynecol*, 199:62.e1-6, 2008.
173. McClain MR, Lambert-Messerlian G, Haddow JE, **Palomaki GE**, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME: Sequential first and second trimester TSH, T4, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) *Am J Obstet Gynecol*, 199:129.e1-129.e6, 2008.
174. Haddow JE, McClain M, Lambert-Messerlian G, **Palomaki GE**, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME: Variability in TSH Suppression by hCG During Early Pregnancy: A FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study, *J Clin Endocrinol Metab*, 93:3341-3347, 2008.
175. Teutsch SM, Bradley LA, **Palomaki GE**, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. *Genet Med*, 11:3-14,2009.
176. **Palomaki GE**, Bradley LA, Douglas MP, Dotson DW, Kolor K: Can *UGT1A1* genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?: an evidence-based review, *Genet Med*, 11:21-34, 2009.
177. **Palomaki GE**, McClain MR, Melillo S, Hampel HL, Thibodeau SN: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med*, 11:42-65, 2009.
178. Lambert-Messerlian, G, **Palomaki GE**, Canick JA: Adjustment of serum markers in the first trimester. *J Med Screen*, 16:102-103, 2009.
179. Marcos J, Craig WY, **Palomaki GE**, Kloza EM, Haddow JE, Roberson M, Bradley LA, Shackleton CHL. Maternal urine and serum steroid measurements to identify steroid sulfatase deficiency (STSD) in second trimester pregnancies. *Prenat Diagn*, 21:771-780, 2009.
180. **Palomaki GE**, Lee JE, Canick JA, McDowell GA, Donnenfeld AE; for the ACMG Laboratory Quality Assurance Committee: Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. *Genet Med*, 11:669-681, 2009.
181. Lambert-Messerlian G, **Palomaki GE**, Neveux LM, Chien E, Friedman A, Rosene-Montella K, Hayes M, Canick JA: Early onset preeclampsia and second trimester serum markers. *Prenat Diagn*, 29:1109-1117, 2009.
182. Mvundura M, Grosse SD, Hampel H, **Palomaki GE**: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med*, 12:93-104, 2010.
183. **Palomaki GE**, Melillo S, Bradley, LA: The association between 9p21 genomic markers and heart disease: a meta-analysis of clinical validity. *JAMA*, 303:648-656, 2010.

184. **Palomaki GE**, Knight GJ, Lambert-Messerlian G, Canick JA, Haddow JE: Four years' experience with an inter-laboratory comparison program involving first trimester markers of Down syndrome. *Arch Pathol Lab Med*, 134:1685-1691, 2010.
185. MacRae AR, Chodirker BN, Davies GA, **Palomaki GE**, Knight GJ, Minett J, Kavsak PA, Toi A, Chitayat D, Van Caesele PG: Second and first trimester estimation of risk for Down syndrome: implementation and performance in the SAFER study. *Prenat Diagn*, 30:459-466, 2010.
186. Haddow JE, Cleary-Goldman J, McClain MR, **Palomaki GE**, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and pre-term delivery. *Obstet Gynecol*, 116:58-62, 2010.
187. Craig WY, Roberson M, **Palomaki GE**, Shackleton CHL, Marco J, Haddow JE: Prevalence of steroid sulfatase deficiency according to race and ethnicity. *Prenat Diagn*, 30:893-898, 2010.
188. Lambert-Messerlian G, **Palomaki GE**, Canick JA: Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access platform: suitability for use in first trimester Down's syndrome screening. *J Med Screen*, 17:109-113, 2010.
189. **Palomaki GE**, Melillo S, Neveux LM, Douglas MP, Dotson DW, Janssens ACJW, Balkite, EA, Bradley LA: Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies. *Genet Med*, 12:772-784, 2010.
190. Haddow JE, McClain MR, **Palomaki GE**, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME for the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. *Obstet Gynecol*, 117:287-292, 2011.
191. Sprawka N, Lambert-Messerlian G, **Palomaki GE**, Eklund EE, Canick JA: Adjustment of maternal serum alpha-fetoprotein levels in women with pregestational diabetes. *Prenat Diagn*, 31:282-285, 2011.
192. Zhang J, Lambert-Messerlian G, **Palomaki GE**, Canick JA: Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters. *Prenat Diagn*, 31:583-588, 2011.
193. Haddow JE, **Palomaki GE**: An introduction to assessing genomic screening and diagnostic tests. *Nutr Today*, 46:162-168, 2011.
194. Haddow JE, Neveux LM, **Palomaki GE**, Lambert-Messerlian G, Canick JA, Grenache DG, Lu J: The relationship between PTH and 25-hydroxy vitamin D in pregnancy. *Clin Endocrinol (Oxf)*, 75:309-314, 2011.
195. Devaney SA, **Palomaki GE**, Scott JA, Bianchi DW: Noninvasive fetal sex determination using cell-free fetal DNA: A systematic review and meta-analysis. *JAMA*, 306:627-636, 2011.
196. **Palomaki GE**, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. *Genet Med*, 13:913-920, 2011.
197. Haddow JE, **Palomaki GE**: Screening to detect Lynch syndrome and prevent hereditary cancers in relatives. *J Med Screen*, 18:167-168, 2011. (December)
198. Palomaki GE, Richards CS: Assessing the analytic validity of molecular testing for Huntington disease using data from an external proficiency testing survey. *Genet Med*, 14:69-75, 2012. (January)
199. Bradley LA, Palomaki GE, Bienstock J, Varga E, Scott JA: Can factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes? Results from a targeted evidence-based review. *Genet Med*, 14:39-50, 2012. (January)
200. Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, Spratt DI, **Palomaki GE**, Neveux LM, Haddow JE: Mid-gestational maternal free thyroxine concentration and offspring neurocognitive development at age two years. *J Clin Endocrinol Metab*, 97:E22-E28, 2012 (January).
201. **Palomaki GE**, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: An international collaborative study. *Genet Med*, 14:296-305, 2012. (March 2012).

202. Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, **Palomaki GE**: DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. *Prenat Diagn*, 32:780-784, 2012 (August).
203. Canick JE, **Palomaki GE**: Maternal plasma DNA: A major step forward in prenatal testing. Invited editorial. *J Med Screen*, 19:57-59, 2012.
204. Lyon E, Foster JG, **Palomaki GE**, Pratt VM, Reynolds K, Sabato MF, Vitazka P: Laboratory testing of *CYP2D6* alleles for tamoxifen testing. *Genet Med*, 14:990-1000, 2012 (December).
205. **Palomaki GE**, Melillo S, Marrone M, Douglas MP: Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review, *Genet Med*, 15:600-611, 2013. PMID: 23492876.
206. Bradley LA, **Palomaki GE**, Gutman S, Samson D, Aronson N: Comparative effectiveness review: Prostate cancer antigen 3 (PCA3) testing for the diagnosis and management of prostate cancer. *J Urol*, 190:389-398, 2013. PMID: 23545099.
207. Jensen TJ, Zwiefelhofer T, Tim RC, Dzakula Z, Kim SK, Mazloom AR, Zhu Z, Tynan J, Lu T, McLennan G, **Palomaki GE**, Canick JA, Oeth P, Deciu C, van den Boom D, Ehrich M: High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma. *PLoS One*, 8:e57381, 2013. PMID: 23483908.
208. Haddow JE, Craig WY, **Palomaki GE**, Neveux LM, Lambert-Messerlian G, Canick JA, Malone F, D'Alton M: Impact of adjusting for the reciprocal relationship between maternal weight and free thyroxine during early pregnancy. *Thyroid*, 23:225-230, 2013. PMID: 23136959.
209. Mazloom A, Dzakula Z, Wang H, Oeth P, Jensen T, Tynan J, McCullough R, Saldivar JS, Ehrich M, van den Boom D, Bombard A, Maeder M, McLennan G, Meschino W, **Palomaki G**, Canick J, Deciu C: Non-invasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. *Prenat Diagn*, 33:591-597, 2013. PMID: 23592550.
210. Canick JA, **Palomaki GE**, Kloza EM, Lambert-Messerlian GM, Haddow JE: The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. *Prenat Diagn*, 33:667-674, 2013. PMID: 23592541.
211. Craig WY, **Palomaki GE**, Neveux LM, Haddow JE: Maternal body mass index during pregnancy and offspring neurocognitive development. *Obstet Med*, 6:20-25, 2013.
212. Lambert-Messerlian G, Kloza EM, Williams J 3rd, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, DePiasio P, Borrell A, Ehrich M, van den Boom D, Bombard AT, Deciu C, **Palomaki GE**: Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies. *Genet Med*, doi:10.1038/gim.2013.149, 2013. PMID: 24091801.
213. **Palomaki GE**, Knight, GJ, Ashwood ER, Best RG, Haddow JE: Screening for Down syndrome in the United States: Results of Surveys in 2011 and 2012. *Arch Pathol Lab Med*, 137:921-926, 2013. PMID: 23808464.
214. Richards CS, **Palomaki GE**, Lacbawan FL, Lyon E, Feldman GL: Three-year experience of a CAP/ACMG methods-based external proficiency testing program for laboratories offering DNA sequencing for rare inherited disorders. *Genet Med*, 16:25-32, 2014. PMID: 23703682.
215. Lambert-Messerlian G, Kloza EM, **Palomaki GE**, Williams J, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, Ehrich M, van den Boom D, Bombard AT, Deciu C, Canick JA: Cell free fetal DNA in maternal plasma of pregnancies achieved by assisted reproductive technologies. *Prenat Diagn*, in press, 2014.
216. Feldman GL, Schrijver I, Lyon E, **Palomaki GE**: Results of the College of American Pathology (CAP)/American College of Medical Genetics and Genomics (ACMG) External Proficiency Testing from 2006 to 2013 for Three Conditions Prevalent in the Ashkenazi Jewish Population. *Genet Med*, accepted for publication, 2014.
217. O'Brien BM, Kloza EM, Haddow PK, Halliday JV, Canick JA, Lambert-Messerlian GM, **Palomaki GE**: Maternal plasma DNA testing for aneuploidy: Evaluation of commercial patient education materials. *J Genet Counsel*, submitted, 2014.

OTHER-PEER-REVIEWED PUBLICATIONS

1. **Palomaki GE**, Knight GJ, Kloza EM, Haddow JE: Maternal weight adjustment and low serum alpha-fetoprotein values. *Lancet*, i:468, 1985.
2. Knight GJ, **Palomaki GE**, Haddow JE: Maternal serum alpha-fetoprotein: a problem with a test kit. *N Engl J Med*, 314:516, 1986.
3. Haddow JE, **Palomaki GE**, Wald NJ, Cuckle HS: Maternal serum alpha-fetoprotein screening for Down syndrome and repeat testing. *Lancet*, ii:1460, 1986.
4. Haddow JE, **Palomaki GE**, Knight GJ: Use of serum cotinine to assess the accuracy of self reported non-smoking. *Br Med J (Clin Res Ed)*, 293:1306, 1986.
5. **Palomaki GE**: Collaborative study of Down syndrome screening using maternal serum alpha-fetoprotein and maternal age. *Lancet*, ii:1460, 1986.
6. **Palomaki GE**, Haddow JE: Combining maternal age and serum alpha-fetoprotein in predicting the risk of Down syndrome. *Obstet Gynecol*, 69:683, 1987.
7. **Palomaki GE**, Knight GJ, Haddow JE: Screening for Down's syndrome. *N Engl J Med*, 318:928, 1988.
8. Knight GJ, **Palomaki GE**, Haddow JE: Quality assurance in MSAFP screening: Authors reply. *Contemp OB/GYN*, 30:16-24, 1988.
9. Greene MF, Haddow JE, **Palomaki GE**, Knight GJ: Maternal serum alpha-fetoprotein levels in diabetic pregnancies. *Lancet*, ii:345-346, 1988.
10. Knight GJ, **Palomaki GE**: Is screening volume the limiting factor in MSAFP screening? *Clin Chem Newsletter*, 3:4-5, 1988.
11. Cuckle HS, Wald NJ, Barkai G, Fuhrmann W, Altland K, Brambati B, Knight GJ, **Palomaki GE**, Haddow JE: First trimester biochemical screening for Down's syndrome. *Lancet*, ii:851-852, 1988.
12. Knight GJ, Haddow JE, **Palomaki GE**, Canick JA: Modification of an unconjugated estriol kit for Down syndrome screening in the second trimester of pregnancy. *Clin Chem*, 34:1206, 1988.
13. Wald NJ, Cuckle HS, Densem J, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, **Palomaki GE**, Canick J: Serum screening for Down's syndrome in early pregnancy. *BMJ*, 298:50, 1989.
14. Osathanondh R, Canick JA, Abell KB, Stevens LD, **Palomaki GE**, Knight GJ, Haddow JE: Second trimester screening for trisomy 21. *Lancet*, ii:52, 1989.
15. Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, **Palomaki GE**: The effects of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated aetrial, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. *Br J Obstet Gynaecol*, 97:272-274, 1990.
16. Haddow JE, **Palomaki GE**, Knight GJ, Canick JA, Wald NJ, Cuckle HS: Maternal serum unconjugated estriol levels are lower in the presence of fetal Down syndrome. *Am J Obstet Gynecol*, 163:1372-1374, 1990.
17. Canick JA, **Palomaki GE**, Osathanondh R: Prenatal screening for trisomy 18 in the second trimester. *Prenat Diagn*, 10:546-548, 1990.
18. Wald NJ, Cuckle HS, Haddow JE, Doherty RA, Knight GJ, **Palomaki GE**: The ultrasonographic diagnosis of fetal open spina bifida. *N Engl J Med*, 324:770-771, 1991.
19. Haddow JE, Knight GJ, **Palomaki GE**, Johnson AM: Maternal serum alpha-fetoprotein in congenital hypothyroidism. *Lancet*, 337:922, 1991.
20. Wald NJ, Densem JW, Haddow JE, **Palomaki GE**, Knight GJ, Canick JA: Prenatal screening for Down's syndrome. *BMJ*, 303:715, 1991.
21. Haddow JE, Holman MS, **Palomaki GE**: Can gestational dates routinely derived from very early ultrasound be used to interpret maternal serum alpha-fetoprotein measurements? *Prenat Diagn*, 12:65-68, 1992.
22. Haddow JE, **Palomaki GE**, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Bowers GB: Dépistage prénatal de la trisomie 21 à l'aide de marqueurs sériques maternels. *Journal International de Médecine*, 248:33-40, 1992.
23. **Palomaki GE**, Haddow JE: Is it time for population-based prenatal screening for fragile-X? *Lancet*, 341:373-374, 1993.

24. **Palomaki GE:** Un protocollo di screening per identificare la trisomia 18 fetale con marcatori nel siero materno. *Ligand Quarterly*, 12:312-317, 1993.
25. **Palomaki GE, Knight GJ, Haddow JE:** Is MoM bashing justified? *Am J Hum Genet*, 53:777-781, 1993.
26. **Haddow JE, Palomaki GE, Chilmonczyk BA:** Hazards of active and passive smoking. *N Engl J Med*, 329:1580-1581, 1993.
27. **Knight GJ, Palomaki GE, Haddow JE, Miller WA, Bersinger NA, Schneider H:** Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy. *Prenat Diagn*, 13:222-223, 1993.
28. **Palomaki GE, Knight GJ, Haddow JE:** Calculating amniotic fluid alpha-fetoprotein median values in the first trimester. *Prenat Diagn*, 13:887-889, 1993.
29. **Haddow JE, Knight GJ, Palomaki GE:** Antenatal screening for Down's syndrome. Performance of different markers remains confused. *BMJ*, 307:679-680, 1993.
30. **Donnenfeld AE, Pulkkinen A, Palomaki GE, Knight GJ, Haddow JE:** Simultaneous fetal and maternal cotinine levels in pregnant women smokers. *Am J Obstet Gynecol*, 168:781-782, 1993.
31. **Palomaki GE, Bradley LA, Haddow JE:** A new approach to analysing fluorescence in situ hybridization data for rapid detection of aneuploidy in amniocytes. *J Med Screen*, 1:96-97, 1994.
32. **Haddow JE, Palomaki GE:** Multiparity and Down's syndrome. *Lancet*, 344:956, 1994.
33. **Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Johnson DA, Haddow JE:** Prenatal screening for cystic fibrosis. *Lancet*, 343:172, 1994.
34. **Haddow JE, Knight GJ, Palomaki GE:** Prenatal ultrasound screening and perinatal outcome. *N Engl J Med*, 330:571, 1994.
35. **Palomaki GE, Haddow JE:** Comparison of two Down syndrome screening strategies for women aged 35 and older. *Prenat Diagn*, 14:898-899, 1994.
36. **Haddow JE, Palomaki GE:** Is maternal obesity a risk factor for open neural tube defects? *Am J Obstet Gynecol*, 172:245-247, 1995.
37. **Haddow JE, Palomaki GE:** Use of personal records for research purposes. Restrictions unnecessary and obstructive. *BMJ*, 310:258, 1995.
38. **Haddow JE, Palomaki GE, Sepulveda D:** Smoking cessation counseling during routine public prenatal care. *Am J Public Health*, 85:1451-1452, 1995.
39. **Wald NJ, Kennard A, Watt H, Haddow JE, Palomaki GE, Knight GJ, Canick JA:** Decision analysis and screening for Down's syndrome. Testing should be in all women. *BMJ*, 311:1372-1373, 1995.
40. **Palomaki GE, Haddow JE:** Can the risk for Down syndrome be reliably modified by second-trimester ultrasonography? *Am J Obstet Gynecol*, 173:1639-1640, 1995.
41. **Palomaki GE, Neveux LM, Haddow JE:** Are DADs (discriminant aneuploidy detection) as good as MoMs (multiples of the median)? *Am J Obstet Gynecol*, 173:1895-1897, 1995.
42. **Knight GJ, Palomaki GE:** Epidemiologic monitoring and quality control of prenatal screening. *Proc UK NEQAS Meeting 1994*, 1:120-126, 1995.
43. **Palomaki GE, Haddow JE, Beauregard LJ:** Prenatal screening for Down's syndrome in Maine, 1980 to 1993. *N Engl J Med*, 334:1409-1410, 1996.
44. **Knight GJ, Haddow JE, Palomaki GE, Donhowe JM, Witte DL:** Computer software programs and Down's syndrome risk calculations. *Lancet*, 347:1553, 1996.
45. **Palomaki GE, Haddow JE:** Prenatal serum markers and trisomy 18. *Prenat Diagn*, 16:477-478, 1996.
46. **Haddow JE, Palomaki GE, Knight GJ, Williams J, Chilmonczyk BA:** Intervening to reduce environmental tobacco smoke exposure in infants. *Pediatrics*, 98:513, 1996.
47. **Palomaki GE, Haddow JE:** Nicked free beta-subunit and Down syndrome screening. *Am J Obstet Gynecol*, 175:1075, 1996.
48. **Palomaki GE, Haddow JE:** Gestational dating and Down's syndrome screening. *Ann Clin Biochem*, 33:359-361, 1996.
49. **Haddow JE, Palomaki GE:** Down's syndrome screening. *Lancet*, 347:1625, 1996.
50. **Haddow JE, Palomaki GE:** Similarities in women's decision-making in the U.S. and U.K. during prenatal screening for Down's syndrome. *Prenat Diagn*, 16:1161-1162, 1996.

51. Lambert-Messerlian GM, Canick JA, **Palomaki GE**: Maternal serum total activin A in pregnancies affected with fetal Down syndrome. *J Med Screen*, 3:217, 1996.
52. Haddow JE, **Palomaki GE**, Bradley LA, Doherty RA: Screening for cystic fibrosis. *JAMA*, 279:1068, 1998.
53. **Palomaki GE**, Neveux LM, Haddow JE: Current Down syndrome risk estimates are reliable. *Am J Obstet Gynecol*, 178:871-872, 1998.
54. **Palomaki GE**, Williams JR, Haddow JE: Prenatal screening for open neural-tube defects in Maine. *N Engl J Med*, 340:1049-1050, 1999.
55. **Palomaki GE**, Haddow JE: Age-related prevalence of Down syndrome. *Am J Obstet Gynecol*, 180:1597-1598, 1999.
56. Haddow JE, **Palomaki GE**, Knight GJ: Response to Hallahan et al., *Prenat Diagn*, 20:790-791, 2000 [Letter to the Editor].
57. Haddow JE, **Palomaki GE**, Williams J: Thyroid-stimulating-hormone concentrations and risk of hypothyroidism. *Lancet*, 360:2081-2082, 2002.
58. **Palomaki GE**, Williams J, Haddow JE: Comparing the observed and predicted effectiveness of folic acid fortification in preventing neural tube defects. *J Med Screen*, 10:52-53, 2003.
59. Lambert-Messerlian G, Halliday J, Williams J, Cain R, Msall ME, **Palomaki GE**, Canick JA: Effect of folic acid fortification on prevalence of neural tube defects in Rhode Island. *J Med Screen*, 11:106-107, 2004.
60. McClain MR, **Palomaki GE**, Haddow JE: Is first trimester measurement of sex hormone binding globulin a possible screening test for gestational diabetes? *Am J Obstet Gynecol*, 190:1808-1809, 2004.
61. **Palomaki GE**: Prenatal screening for cystic fibrosis: An early report card (editorial). *Genet Med*, 6:115, 2004.
62. **Palomaki GE**, Knight GJ, Neveux LM, Haddow JE, Pandian R: First-trimester Down syndrome screening (Response to Hallahan). *Clin Chem*, 52:161, 2006.
63. Haddow JE, **Palomaki GE**, McClain MR: Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. *Obstet Gynecol*, 107:205-206, 2006.
64. McClain MR, **Palomaki GE**, Haddow JE: How reliable are *BRCA1/2* mutation estimates? *Cancer Res*, 67:5057, 2007.
65. de LaChappelle A, **Palomaki GE**, Hampel H: Identifying Lynch syndrome. *Int J Cancer*, 125:1492-1493, 2009.
66. Ashwood ER, **Palomaki GE**: A new era in noninvasive prenatal testing. *N Engl J Med*, 369:2164, 2013.

BOOKS AND BOOK CHAPTERS

1. Ritchie RF, Smith DE, Turgeon W, **Palomaki GE**: Interpretation of serum proteins. *In*: Protein Abnormalities, Volume 1. Physiology of Immunoglobulins: Diagnostic and Clinical Aspects. Ritzmann, SE (ed), Alan R. Liss, New York, p. 159-190, 1982.
2. Haddow JE, Knight GJ, **Palomaki GE**: Prospects of Screening for Fetal Chromosomal Aberrations in the First Trimester of Pregnancy Using Maternal Serum. *In*: First Trimester Genetic Diagnosis and Therapy: Current Status/Future Prospects. Oxford University Press, 1987.
3. Haddow JE, **Palomaki GE**, Knight GJ, Kloza EM, Hitchcock J: Prenatal Screening for Major Fetal Disorders. Vol. I: Fetal Disorders Associated with Elevated MSAFP Values. JE Haddow (ed), published at Foundation for Blood Research, 1990.
4. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, **Palomaki GE**, Hitchcox S, White BW, Himmelfarb J, Leeber DA: 1. Flow Cytometric Crossmatch Graft Survival. 2. Positive B Cell Flow Cytometric Crossmatch and Early Graft Loss. 3. Re graft Survival in Positive Flow Cytometric Crossmatch Patients by Length of Previous Graft Survival. *In*: Terasaki PI (ed), Visuals of the Clinical Histocompatibility Workshop. One Lambda, Inc., Los Angeles, CA, pp. 29, 41, 43, 1990.
5. Haddow JE, **Palomaki GE**: Maternal Protein Enzyme Analyses. *In*: Medicine of the Fetus & Mother. EA Reece, JC Hobbins, MJ Mahoney, and RH Petrie (eds), J.B. Lippincott Company, pp. 653-667, 1992.

6. Knight GJ, **Palomaki GE**: Maternal Serum Alpha-fetoprotein and the Detection of Open Neural Tube Defects. *In: Maternal Serum Screening for Fetal Genetic Disorders.* S Elias, JL Simpson (eds), Churchill Livingstone, pp. 41-58, 1992.
7. Haddow JE, Knight GJ, **Palomaki GE**: Measuring serum cotinine to aid in smoking cessation during pregnancy and to enhance assessment of smoking-related fetal morbidity. *In: Effects of Smoking on the Fetus, Neonate, and Child.* Poswillo D, Alberman E (eds), Oxford University Press, pp. 207-222, 1992.
8. Haddow JE, **Palomaki GE**: Prenatal Screening for Down Syndrome. *In: Essentials of Prenatal Diagnosis.* JL Simpson, S Elias (eds), Churchill Livingstone, pp. 185-220, 1993.
9. Knight GJ, **Palomaki GE**, Haddow JE: Alpha-fetoprotein screening for neural tube defects. *In: When to Screen in Obstetrics & Gynaecology.* W.B. Saunders Co., Ltd., Wildschut HIJ, Weiner CP, Peters TJ (eds), pp. 72-80, 1996.
10. Knight GJ, **Palomaki GE**, Haddow JE: Triple marker screening for fetal Down syndrome. *In: When to Screen in Obstetrics & Gynecology.* Wildschut HIJ, Weiner CP, Peters TJ (eds), W.B. Saunders Co., Ltd., pp. 80-87, 1996.
11. Haddow JE, **Palomaki GE**: Biochemical Screening for Neural Tube Defects and Down Syndrome. *In: Fetal Medicine: Basic Science and Clinical Practice.* Rodeck CH, Whittle MJ (eds), Churchill Livingstone: London, 373-388, 1999.
12. Haddow JE, **Palomaki GE**: Biochemical Markers of Fetal Disorders in Maternal Serum and Amniotic Fluid. *In: Medicine of the Fetus & Mother, Second Edition.* Reece EA, Hobbins JC (eds), J.B. Lippincott Co., pp. 689-706, 1999.
13. **Palomaki GE**: The Role of Down Syndrome Risk Assessment Models in Policy. *In: Down Syndrome: Screening Policy and Economic Evaluations.* Beazoglou T, Benn P, Cuckle H, Haddow JE, Kryiopoulos J (eds), Exandas Publishers, pp. 55-68, 1999.
14. McClain MR, **Palomaki GE**, Bradley LA, Coates RJ: Public health assessment of *BRCA1* and *BRCA2* testing for breast and ovarian cancer. *In: Genomics and Population Health: United States 2003.* Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention. Atlanta, Georgia, 2004, pp. 23-30.
15. Haddow JE, **Palomaki GE**: ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. *In: Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease.* Khoury M, Little J, Burke W (eds), Oxford University Press, pp. 217-233, 2003.
16. **Palomaki GE**, McClain MR, Haddow JE. ACCE reviews of genetic tests: *BRCA1*, *BRCA2*, and *CFTR*. *In: Genomics and Population Health: United States 2005.* Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention. Atlanta, Georgia, 2005, pp. 27-33. Also available at <http://www.cdc.gov/genomics/activities/ogdp/2005.htm>.
17. Haddow JE, **Palomaki GE**, Wapner RJ: First- and second-trimester screening for open neural tube defects and Down syndrome. Chapter 28. *In: Clinical Obstetrics: the Fetus & Mother Handbook.* Third Edition. Reece EA, Hobbins JC, (eds), 3rd Edition, Blackwell Publishing Ltd, pp. 485-503, 2007.
18. Haddow JE, **Palomaki GE**, Canick JA, Knight GJ: Prenatal screening for open neural tube defects and Down's syndrome. *In: Fetal Medicine: Basic Science and Clinical Practice.* Rodeck CH, Whittle MJ (eds), Churchill Livingstone: London, 243-264, 2009.
19. Teutsch SM, Bradley LA, **Palomaki GE**, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP working group. *In: Human Genome Epidemiology, 2nd Edition.* Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 458-481, 2010.
20. Gudgeon JM, **Palomaki GE**, Williams MS: Rapid evidence-based reviews of genetic tests. *In: Human Genome Epidemiology, 2nd Edition.* Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, 482-496, 2010.
21. McClain MR, **Palomaki GE**, Piper M, Haddow JE: A Rapid-ACCE Review of *CYP2C9* and *VKORC1* allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious

bleeding. *In: Human Genome Epidemiology, 2nd Edition.* Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 620-638, 2010.

PUBLICATIONS SUBMITTED OR IN PREPARATION

ABSTRACTS/POSTER SESSIONS

1. Kloza EM, Palomaki GE, Mahoney RJ, Brewster TG: Genetic determination of paternity. The Eighth Annual Maine Biological and Medical Science Symposium, May, 1982.
2. Palomaki GE, Adams RJ, Mahoney RJ: Simulation of non-disputed paternity testing. The Ninth Annual Maine Biological and Medical Science Symposium, May 25-26, 1983.
3. Knight GJ, Haddow JE, Palomaki GE, Kloza EM: Cotinine vs. self-reported cigarette consumption as predictors of birthweight (APS-SPR Meeting), May 6-9, 1985.
4. Knight GJ, Palomaki GE, Holman MS, Haddow JE: External quality assessment of laboratories performing AFP screening. American Public Health Association, 114th Annual Meeting. Las Vegas, Nevada, September 28-October 2, 1986.
5. Kloza EM, Hill LE, Palomaki GE: Counseling issues for Down syndrome using maternal serum alpha-fetoprotein. National Society of Genetic Counselors, Sixth Annual Education Conference: Strategies in Genetic Counseling: The Challenge of the Future, October 30-November 1, 1986.
6. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Low second trimester maternal serum unconjugated estriol in Down syndrome pregnancies. *Am J Hum Genet Suppl*, 41:a269, 1987.
7. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, Palomaki GE, Hitchcox S, White BW, Himmelfarb J, Leeber DA: The flow cytometric crossmatch and early renal transplant loss. Fourteenth Annual Meeting of the American Society for Histocompatibility and Immunogenetics. San Francisco, CA, October 16-20, 1988.
8. Steinort K, Knight GJ, Haddow JE, Palomaki GE: Biochemical measurements and passive tobacco smoke exposure. Fourteenth Annual Maine Biological and Medical Symposium, May, 1988.
9. Lambert DA, Keilson LM, Palomaki GE: Hypothermia among tri athletes during an ocean swim, Maine 1983. American Public Health Association, November 13-17, 1988.
10. Canick JA, Sung J, Singer DB, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Second trimester maternal serum estriol, progesterone, SP1, and alpha-fetoprotein in Down syndrome pregnancy: Relationship to fetal adrenal, fetal liver, and placental mass. Endocrine Society Meeting, 1988.
11. Haddow JE, Palomaki GE, Knight GJ, Wald NJ, Williams J: Cotinine-assisted intervention to reduce smoking in pregnancy. Society for Pediatric Research, 1989.
12. Chilmonczyk BA, Knight GJ, Williams J, Pulkkinen AJ, Palomaki GE, Haddow JE: Urinary cotinine to evaluate passive smoke exposure in infancy. Society for Pediatric Research, 1989.
13. Palomaki GE, Donnenfeld AE, Lea DH, Williams JR: The incidence of Tay-Sachs disease in French-Canadians: A ten year experience in Maine. Seventh Annual Eastern Canadian/New England Clinical Genetics Conference, May 12, 1989.
14. Johnson AM, Palomaki GE, Haddow JE: Adjustment of maternal serum alpha-fetoprotein (MSAFP) levels for race and for maternal weight in screening for fetal open spina bifida: A United States collaborative study. American Society of Human Genetics, May, 1989.
15. Canick JA, Stevens LD, Abell KB, Panizza DS, Osathanondh R, Knight GJ, Palomaki GE, Haddow JE: Second trimester maternal serum unconjugated estriol and human chorionic gonadotropin in pregnancies affected with fetal Trisomy 18, anencephaly, and open spina bifida. American Society of Human Genetics, November 12-15, 1989.
16. Knight GJ, Palomaki GE, Haddow JE, Johnson AM, Osathanondh R, Canick JA: Maternal serum levels of the placental products hCG, hPL, SP1, and progesterone are all elevated in cases of fetal Down syndrome. American Society of Human Genetics, November 12-15, 1989.
17. Knight GJ, Haddow JE, Palomaki GE: Epidemiological studies of smoking and birthweight using a biochemical marker. Bingham Consortium for Health Research, October, 1989.

18. Haddow JE, Hitchcock JL, Knight GJ, Kloza EM, **Palomaki GE**, Wald NJ: Cotinine-assisted intervention with smoking by pregnant women. Bingham Consortium for Health Research, October, 1989.
19. **Palomaki GE**, Haddow, JE, Knight GJ: Maternal serum screening for Down syndrome in early pregnancy. Bingham Consortium for Health Research, October, 1989.
20. Craig WY, **Palomaki GE**, Haddow JE: Cigarette smoking and serum lipid and lipoprotein levels in adults and in the 8-19 year age group: An analysis of published data. Bingham Consortium for Health Research, October, 1989.
21. Donnenfeld AE, Pulkkinen AJ, **Palomaki GE**, Knight GJ, Haddow JE: Serum cotinine levels in non-pregnant adult smokers, pregnant mothers who smoke, and exposed fetuses. American Society of Human Genetics, November 12-18, 1989.
22. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, **Palomaki GE**, Hitchcox S, White BW, Himmelfarb J, Leeber DA: 1. Flow Cytometric Crossmatch Graft Survival. 2. Positive B Cell Flow Cytometric Crossmatch and Early Graft Loss. 3. Regraft Survival in Positive Flow Cytometric Crossmatch Patients by Length of Previous Graft Survival. Fourth Annual Clinical Histocompatibility Workshop, Kahuku, Oahu, Hawaii, February 28 - March 4, 1990.
23. Haddow JE, **Palomaki GE**, Knight GJ, Williams JR, Beaugard LJ: The effect of maternal weight adjustment on screening for Down syndrome using maternal serum alpha-fetoprotein and age. 8th International Congress of Human Genetics. *Am J Hum Genet*, 49:222, 1991.
24. **Palomaki GE**, Knight GJ, Haddow JE, Canick JA, Saller DN, Panizza DS, Grant SS, Wenstrom KD, Hudson JD: Prospective trial of a screening protocol to identify Trisomy 18 using maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. 8th International Congress of Human Genetics. *Am J Hum Genet*, 49:227, 1991.
25. Beaugard LJ, **Palomaki GE**, Williams JR, Haddow JE: The pattern of prenatal screening and diagnosis of Down syndrome in Maine: 1980 to 1989. 8th International Congress of Human Genetics. *Am J Hum Genet*, 49:210, 1991.
26. Rose NC, **Palomaki GE**, Haddow JE, Giardine R, Mennuti MT: The effect of maternal weight adjustment on MSAFP screening for Down syndrome in women age 35 and older. 8th International Congress of Human Genetics. *Am J Hum Genet*, 49:216, 1991.
27. Rose NC, **Palomaki GE**, Haddow JE, Senior M, Mennuti MT: The effect of maternal race on maternal serum and amniotic fluid alpha-fetoprotein (AFP) measurements. 8th International Congress of Human Genetics. *Am J Hum Genet*, 49:225, 1991.
28. Rose NC, **Palomaki GE**, Haddow JE, Mennuti MT: Maternal serum alpha-fetoprotein (MSAFP) screening for Down syndrome in women age 35 and older. 8th International Congress for Human Genetics. *Am J Hum Genet*, 49:229, 1991.
29. **Palomaki GE**, Bennert HW, Willhoite B, Greene, MF: Normalization Methods for Interpreting Glycosylated Hemoglobin During Pregnancy. A poster accepted for and presented at the Pregnancy Satellite Symposium to the 14th International Diabetes Federation Congress, Newport, RI, June 19-22, 1991.
30. Simpson JL, **Palomaki GE**, Elias S, Haddow JE, Andersen R, Brownlee M: Correlation between second and third trimester maternal serum alpha fetoprotein (MSAFP). Society for Gynecologic Investigation, 1991.
31. Rose NC, **Palomaki GE**, Knight GJ, Pulkkinen A, Haddow JE, Donnenfeld AE, Cohen AW, Mennuti MT: Second-trimester diurnal variation of MSAFP, hCG, and uE3: Is it present and does it effect prediction of a patient's risk for fetal Down syndrome? Clinical and Molecular Cytogenetics of Developmental Disorders Conference, July 1992.
32. Haddow JE, **Palomaki GE**, Knight GJ, Cunningham GC, Lustig L, Boyd P: Prenatal screening to reduce the need for amniocentesis in women age 35 and older. *Am J Hum Genet*, 53:a4, 1993.
33. Canick JA, Saller DN, Harle U. Lesser KB, **Palomaki GE**: Is there an association between positive Down syndrome screening results and fetal or neonatal demise? *Am J Hum Genet*, 53:a1387, 1993.
34. Cole LA, Isozaki T, **Palomaki GE**, Canick JA, Iles RK, Cuckle HS: Detection of B-core fragment in second trimester Down's syndrome pregnancies. Congress: Recent Advances in Prenatal Diagnosis for Aneuploidy. Amsterdam, May 1-3, 1996.

35. Haddow JE, **Palomaki GE**, Knight GJ: First trimester screening for Down syndrome using biochemical and ultrasound markers. *Am J Hum Genet*, 59:A41, 1996.
36. **Palomaki GE**, Knight GJ, Fodor KK, Haddow JE: Second trimester screening performance of free b-subunit versus hCG on a population with complete ascertainment of Down syndrome. *Am J Hum Genet*, 59:A327, 1996.
37. Kellner LH, Canick JA, **Palomaki GE**, Saller DN, Lambert-Messerlian GM, Neuer M, Osathanondh R, Bombard AT: Urinary markers: A new approach to screening for Down syndrome in the second trimester. *Am J Hum Genet*, 59:A41, 1996.
38. **Palomaki GE**, Bradley LA, Doherty RA, Haddow JE: Prenatal screening for cystic fibrosis (CF): Is it cost effective for all racial/ethnic groups? *Am J Hum Genet*, 61:119, 1997.
39. **Palomaki GE**: Statistical models used in prenatal diagnosis. Present and future of prenatal diagnosis: A challenge. Ovideo, Spain, September 23-25, 1998.
40. Knight GJ, **Palomaki GE**, Neveux LM, Haddow JE, Bradley LA: Maternal serum dimeric inhibin-A as a second trimester screen for Down syndrome. *Am J Hum Genet*, 63:a166, 1998.
41. Johnson DD, Doherty RA, **Palomaki GE**, Haddow JE: Routine prenatal cystic fibrosis screening in primary care offices. *Am J Hum Genet*, 63:a13, 1998.
42. **Palomaki GE**, Knight GJ, Bradley LA, Haddow JE: Options for incorporating dimeric inhibin-A in second trimester screening programs for Down syndrome. *Am J Hum Genet*, 63:a170, 1998.
43. Strom CM, **Palomaki GE**, Knight GJ, Cole L, Mahoney J, Pandian R: Maternal urine invasive trophoblastic antigen (ITA) is a useful marker for Down syndrome detection in the 1st trimester. Presented at the American Society of Human Genetics Annual Meeting, San Diego, California, October 12-16, 2001.
44. Lee JES, Cole LA, **Palomaki GE**, Mahoney MJ, Benn P, Vendely T, Strom CM, Pandian R: Maternal serum ITA utility for prenatal Down syndrome detection: A pilot study using a new automated assay. Presented at American Society of Human Genetics Annual Meeting, San Diego, California, October 12-16, 2001.
45. **Palomaki GE**, Bradley LA, Richards CS, Grody WW, Stenzel TT, Haddow JE: Estimating analytic validity for *HFE* Testing in the General Population. American College of Medical Genetics, San Diego, CA, March, 2003.
46. **Palomaki GE**, FitzSimmons SC, Bradley LA, Haddow JE: Prenatal screening for cystic fibrosis: Clinical validity in the selected racial/ethnic groups. American College of Medical Genetics, San Diego, CA, March, 2003.
47. Bradley LA, **Palomaki GE**, Hyman D, Richards CS, Haddow JE: Prenatal cystic fibrosis (CF) screening: barrier to demonstrating clinical validity and utility in practice. American College of Medical Genetics, San Diego, CA, March, 2003.
48. **Palomaki GE**, Grosse SD, Haddow JE: The financial cost of prenatal screening for cystic fibrosis in the United States. American College of Medical Genetics, San Diego, CA, March, 2003.
49. Grosse S, **Palomaki G**, Cabal C: Net cost of prenatal screening for cystic fibrosis in the United States and Western Europe. 4th World Congress of the International Health Economics Association, San Francisco, California, June 15-18, 2003.
50. Vendely P, Lu J, Plewnia J, **Palomaki GE**, Knight GJ, Cole LA, Pandian MR: Measurement of second trimester maternal serum invasive trophoblast antigen (ITA) for Down syndrome (DS) screening. *Clin Chem*, 49:A132, 2003.
51. Knight GJ, **Palomaki GE**, Neveux LM, Haddow JE, Bradley LA: Maternal serum dimeric inhibin-A as a second trimester screen for Down syndrome. *Am J Hum Genet*, 63:a166, 1998.
52. Hollowell JG, McClain M, **Palomaki GE**, Haddow JE: Relationships between urinary iodine and total thyroxine (TT4) and thyroid stimulating hormone (TSH) concentrations in the US population (1988-1994 (NHANES III)). 76th Annual Meeting of the American Thyroid Association, Vancouver, British Columbia, September 29-October 3, 2004.
53. **Palomaki GE**, Knight G, Neveux L, Panidan R, Haddow J. Maternal serum invasive trophoblast antigen (ITA) in first trimester trisomy 18 pregnancies. ASHG 2004 Annual Meeting, Toronto, Canada, October 2004.

54. Haddow J, **Palomaki GE**, Knight G, Kloza E. An intervention trial of integrated serum testing (IST) for Down syndrome. ASHG 2004 Annual Meeting, Toronto, Canada, October 2004.
55. **Palomaki G**, Neveux L, Meier C, Wyatt P. Second trimester invasive trophoblast antigen (ITA) as a Down syndrome marker: A prospective cohort study using fresh serum samples. ASHG 2005 Annual Meeting, New Orleans, Louisiana, October 2006.
56. Wyatt P, Meier C, Neveux L, **Palomaki G**. First trimester invasive trophoblast antigen (ITA) as a Down syndrome marker. ASHG 2005 Annual Meeting, New Orleans, Louisiana, October 2006.
57. McClain MR, **Palomaki GE**, Hampel H, Westman JA, Haddow JE. Family history screening for hereditary breast / ovarian cancer in four population -based cohorts. American Association for Cancer Research (AACR) 97th Annual Meeting, Boston, Massachusetts, April, 2006.
58. **Palomaki GE**, Neveux LM, Bahado-Singh RO: Deciding which human chorionic gonadotropin-related molecule to use in a first trimester Down syndrome screening program. ACOG 55th Annual Clinical Meeting, San Diego, CA, May 5-9, 2007, *Obstet Gynecol*, 109 (4 Suppl):93S, 2007.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA:

PEER-REVIEWED

1. DNA Testing Standards: The ACCE Project, a model system to assess the availability, quality, and usefulness of existing data on DNA-based tests and testing algorithms. www.fbr.org/research/acce-cdc/cdcacce-dd.html and www.cdc.gov/genomics/info/reports/research/FBR/ACCE.htm
2. Bradley LA, **Palomaki GE**, Dotson WD, Douglas MP, Kolor K, Whitehead N, Gillis E, Viswanathan M, Gillis E. Evidence Report: Can *UGT1A1* Genotyping Reduce Morbidity and Mortality in Patients with Metastatic Colorectal Cancer Treated with Irinotecan? Pending posting on www.egapreviews.org, 2009.

INVITED PRESENTATIONS

1. The WHO position. Fourth Scarborough Conference on Preventive Medicine (Scarborough, Maine), September 15-17, 1984.
2. More on Distributions and MoMs. Course in Preventive Medicine. Screening for Neural Tube Defects, Down Syndrome, Cystic Fibrosis, and Fragile X. International School of Pediatric Sciences, Genoa, Italy, October 1-3, 1992.
3. Other Methods of Combining Markers. Course in Preventive Medicine. Screening for Neural Tube Defects, Down Syndrome, Cystic Fibrosis, and Fragile X. International School of Pediatric Sciences, Genoa, Italy, October 1-3, 1992.
4. Screening for Fragile X. Course in Preventive Medicine. Screening for Neural Tube Defects, Down Syndrome, Cystic Fibrosis, and Fragile X. International School of Pediatric Sciences, Genoa, Italy, October 1-3, 1992.
5. Prenatal Screening for Down's Syndrome with Maternal Serum Markers. 9th International Neonatal Screening Symposium, Lille, France, September 13, 1993.
6. How to Decide: One, Two, Three or More Markers for Down's Syndrome Testing. American Association of Clinical Chemists (AACC) Annual Meeting New Orleans, LA., July 19, 1994.
7. Principles of Screening. The 8th Congress of the Federation of the Asia/Oceania Perinatal Societies. The 1st Asia-Oceania Workshop on Maternal Serum Screening for Down Syndrome, Taipei, Taiwan, September 16, 1994.
8. Calculating the Risk of Fetal Down Syndrome. The 8th Congress of the Federation of the Asia/Oceania Perinatal Societies. The 1st Asia-Oceania Workshop on Maternal Serum Screening for Down Syndrome, Taipei, Taiwan, September 16, 1994.
9. Specific Factors that Affect Maternal Serum Screening. The 8th Congress of the Federation of the Asia/Oceania Perinatal Societies. The 1st Asia-Oceania Workshop on Maternal Serum Screening for Down Syndrome, Taipei, Taiwan, September 16, 1994.

10. Results of Intervention Trials. The 8th Congress of the Federation of the Asia/Oceania Perinatal Societies. The 1st Asia-Oceania Workshop on Maternal Serum Screening for Down Syndrome, Taipei, Taiwan, September 16, 1994.
11. Use of FISH as a screening test, "Nuchal Translucency", Trisomy 18 Testing", and several topics concerning prenatal screening for fragile X. Workshop on Strategies in Antenatal Screening: Cystic Fibrosis, Down's Syndrome and Fragile X, sponsored by the Wolfson Institute, March 13th, 1995.
12. Prenatal Screening for Neural Tube Defects and Down Syndrome. 21st National and 1st International Meeting of the Clinical Ligand Assay Society, Toronto, Canada, May 24, 1995.
13. Expectations for Prenatal Screening Based on Case-Control Studies and Intervention Trials. First Educational Seminar on Fetal Screening, sponsored by "The Predictive Medicine Research Institute, Tokyo, Japan, September 24, 1995.
14. Prenatal Screening Tests. National Society of Genetic Counselors Annual Meeting October 28, 1995.
15. Intensive Course on Screening for Down's Syndrome, sponsored by the Wolfson Institute of Preventive Medicine, London, England. Talks included "Understanding MoMs, distributions and Regression", "Truncation Limits, Distribution Parameters and Selecting Cut-off Levels", "Ultrasound as a screening test for Down's syndrome in first and second trimester", "Other Factors Affecting Serum Markers", "Results of Screening in Practice" and "Serum Markers and Trisomy 18". Three day courses held February 18, 1996.
16. Down's Syndrome Epidemiology and Risk Estimation. Recent Advances in Prenatal Diagnosis for Aneuploidy, Amsterdam, The Netherlands, May 1, 1996.
17. Screening for Chromosomal Defects: Where Do We Go From Here? Pacific Southwest Regional Genetics Network Conference, San Diego, CA, September 27, 1996.
18. First Trimester Biochemical Screening for Down Syndrome OB/GYN Geneticists Meeting (Held in association with ASHG), San Francisco, CA, October 31, 1996.
19. American Association of Clinical Chemists (AACC) Full day Workshop "Uses and Interpretations of Prenatal Markers"
 July 17, 1994, New Orleans, LA
 July 16, 1995, Anaheim, CA
 July 20, 1997, Atlanta, GA
20. The Role of Down Syndrome Risk Assessment Models in Policy Making. Down Syndrome Screening Policy and Economic Evaluation, Athens, Greece, March 6, 1997.
21. Is Prenatal Screening Working as Predicted and How is it Being Used in the World Today? Meeting of International Users of DSL Diagnostic Products. Milan, Italy, October 15, 1997.
22. Prenatal Screening for Cystic Fibrosis: A Cost Analysis. American Society of Human Genetics (ASHG) Slide Presentation, Baltimore, Maryland, October 31, 1997.
23. Status of Genetic Testing for Cystic Fibrosis. Society of Perinatal Obstetricians Annual Meeting, Miami, FL, February 4, 1998.
24. Issues in Implementing Prenatal Screening for Cystic Fibrosis. The Sixth Scarborough Conference, Scarborough, Maine, July 26-28, 1998.
25. 1st and 2nd Trimester Screening for Down Syndrome and Prenatal Screening for Cystic Fibrosis. Mountain States Regional Genetic Services Network Annual Meeting, Steamboat Springs, CO, August 13-15, 1998.
26. Statistical Models Used in Prenatal Diagnosis. Present and Future of Prenatal Diagnosis: A Challenge. IX European Cell Workshop, College of Physicians of Asturias, Oviedo, Spain, September 23-25, 1998.
27. Intensive Short Course on Down's Syndrome Screening, Wolfson Institute of Preventive Medicine, London, England, May 20-22, 1998. Presenter of the following:
 Truncation limits, distribution parameters and selecting cut-offs
 Understanding MoMs, distributions, regressions and likelihood ratios
 Factors affecting serum markers: Twins and diabetes
 Results of screening in practice
 Trisomy 18: serum markers
28. Status of Genetic Testing for Cystic Fibrosis (CF). SPO Meeting, Miami, Florida, 1999.

29. Biostatistical Considerations Pertinent to Prenatal Considerations. 1st National Symposium Developments in Prenatal Screening, Montreal, Canada, November 20-21, 1999.
30. Significance of Ultrasound Findings. National Society of Genetic Counselors National Meeting, 1999.
31. The Leading Edge: Advances in Maternal and Fetal Medicine. The Wiggins Symposium, Albuquerque, New Mexico, November 3, 2000.
32. Addition of Dimeric Inhibin-A (DIA) to Second Trimester Maternal Serum Screening Programs for Down Syndrome. Ontario, Canada, November 17, 2000.
33. Developing a Process for Evaluating Genetic Tests. Human Genome Epidemiology Workshop: Developing Guidelines for Evaluating and Integrating Data on Using Genetic Information to Improve Health and Prevent Disease. Centers for Disease Control and Prevention, National Cancer Institute, National Institute for Environmental Health Sciences. Atlanta, Georgia, January 29-30, 2001.
34. Second Trimester Maternal Serum Screening and Smith-Lemli-Opitz Syndrome (SLOS). PDC Directors Meeting, State of California. Oakland, California, March 19, 2001.
35. Medical Screening Issues: Implications for Factor V Leiden. Factor V Leiden: Public Health Implications. Centers for Disease Control, Decatur, Georgia, April 2-3, 2001.
36. Implementing "Quad" Markers: New Developments and Opportunities in Prenatal Screening for Fetal Down Syndrome. London, Ontario, Canada, April 25, 2001.
37. Addition of Dimeric Inhibin-A (DIA) to Second Trimester Maternal Serum Screening Programs for Down Syndrome. Prenatal Symposium. American College of Obstetricians and Gynecologists National, May 1, 2001.
38. Medical Screening. American Society of Clinical Pathologists Teleconference, February 28, 2002.
39. The ACCE Process: A CDC-Funded Project. Presented to CAP/ACMG Biochemical and Molecular Genetics Resource Committee, Jackson Hole, Wyoming, July 7, 2002.
40. Experience from the ACCE Project. Workshop, Public Health Assessment of Genetic Testing. Centers for Disease Control, Atlanta, Georgia. February 28, 2003.
41. Allowing for Smoking. Sixth International Down Syndrome Screening Congress, Regents College, London, England, May 19-20, 2003.
42. Types of Data Needed for Setting Policy. Creating a Framework for Setting Genetic Testing Policy, New England Public Health and Managed Care Collaborative, July 14, 2003.
43. Estimating the Analytic Validity of DNA Testing for Cystic Fibrosis (*CFTR*) Mutations. DNA Technologies in NBS, Washington, DC, September 1, 2004.
44. Analytic Validity: *HFE*, *CFTR* & Factor V Leiden Testing. Public Health Assessment of Genetic Tests for Screening & Prevention. Office of Genomics and Disease Prevention. Centers for Disease Control (CDC) and Foundation for Blood Research, Atlanta Georgia. September 27-28, 2004.
45. The analytic validity of *CFTR* mutation testing in a prenatal screening program for cystic fibrosis. DNA Technologies in Newborn Screening. Washington, DC, September 1, 2004.
46. A Breast/Ovarian Cancer Dataset. Public Health Assessment of Genetic Tests for Screening & Prevention. Office of Genomics and Disease Prevention. Centers for Disease Control (CDC) and Foundation for Blood Research, Atlanta Georgia. September 27-28, 2004.
47. Clinical Utility Overview. Public Health Assessment of Genetic Tests for Screening & Prevention. Office of Genomics and Disease Prevention. Centers for Disease Control (CDC) and Foundation for Blood Research, Atlanta Georgia. September 27-28, 2004.
48. The feasibility of screening for Smith-Lemli-Opitz syndrome: Update on the first 669,340 women screened. American Society of Human Genetics Annual Meeting, Toronto, Canada, October 29, 2004.
49. Integrated Serum Testing. Prenatal Screening: Incorporating the First Trimester Studies. Pregnancy and Perinatology Branch, National Institute of Child Health and Human Development, December 16, 2004.
50. Components of Evaluation: Analytic Validity (AV). Expert Meeting on Evidence-Based Review of Genomic Applications. Westin Peachtree Plaza Hotel, Atlanta, GA, January 24-25, 2005.
51. Prenatal screening protocols for Down syndrome. Genzyme Genetics, Santa Fe, New Mexico, February 8, 2005.

52. Down syndrome screening using maternal serum measurements of Invasive Trophoblast Antigen (ITA): Current knowledge and future applications. Sponsored by Quest Diagnostics, New Orleans, Louisiana, April 2, 2005.
53. Principles of Screening. XIX International Congress of Clinical Chemistry. Orlando, Florida, July 24-28, 2005.
54. First Trimester Screening. XIX International Congress of Clinical Chemistry. Orlando, Florida, July 24-28, 2005.
55. Contingency, Sequential, Repetitive, etc. XIX International Congress of Clinical Chemistry. Orlando, Florida, July 24-28, 2005.
56. Epidemiological Monitoring. XIX International Congress of Clinical Chemistry. Orlando, Florida, July 24-28, 2005.
57. Introduction to prenatal screening; First and integrated screening for Down syndrome; (2 talks) at Beckman Coulter, Inc. Chaska, Minnesota February 6-7, 2006.
58. Introduction to medical statistics. Medical Students, University of New England, Biddeford, Maine, March 10, 2006.
59. Validation of a Repeated Measure Algorithm Using PAPP-A, International Down Syndrome Study Group bi-annual meeting in Amsterdam on May 5 and 6, 2006.
60. Genetic test evaluation: Current practice and developments in the United States Organization for Economic Cooperation and Development (OECD). Manchester, England, June 26-27, 2006.
61. Inherited breast / ovarian cancer: Comparison of family history protocols. Mountain States Regional Genetic Network 2006 Annual Meeting, Denver, Colorado, July 14, 2006.
62. Multiple markers in a clinical setting: Prenatal screening for Down syndrome. Seminar Series: Division of Epidemiology, Statistics and Prevention Research, NICHD, NIH, Washington, DC, July 11, 2006.
63. CYP2D6 and VKORC1 genotyping for Warfarin dosing: An evidence review: For the American College of Medical Genetics: Warfarin/Coumadin PCX Guideline Development Committee, Washington, DC, October 30, 2006.
64. Down syndrome screening: Evaluating performance and choosing cut-off levels. Genzyme Genetics Annual Meeting, Bermuda, January 30, 2007

65. Multiple marker screening in 2007: How best to specific screening performance; Estimating the performance of Integrated, sequential and contingent screening; and New ACMG guidelines for first trimester / integrated screening for Down syndrome (3 talks). Second International conference on the integrated testing in prenatal screening for Down syndrome Providence, Rhode Island, March 30, 2007.
66. Multiple genomic tests in a clinical setting. American Society of Human Genetics Annual Meeting, San Diego, California, October 24, 2007
67. Principals and methods of prenatal screening, Sharp Healthcare's 7th Annual Prenatal Ultrasound Conference, San Diego, California, October 19, 2007.
68. Modeling the impact of a Lynch syndrome program in Maine. Maine Cancer Coalition. November 5, 2007
69. Collection, review and analysis of clinical evidence for genetic testing. Genetic Testing and Genetic Risk Assessment for Health Plans. Washington, DC, November 14, 2007
70. Pharmacogenetics testing: Warfarin dosing in adult patients to avoid serious bleeding. Tufts / NEMC, Boston, Massachusetts, February 11, 2008
71. Circulating cell free fetal RNA: Can it be used as a prenatal test or Down syndrome? Wolfson Institute, London, England, April 16, 2008
72. Preeclampsia and second trimester serum markers, Wolfson Institute, London, England, May 15, 2008
73. NT Quality assessment in North American Laboratories. IDDSG Congress, Vancouver, British Columbia, Canada, May 31, 2008
74. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with Irinotecan?, Supporting policy development in genetics/genomics: Where HTA, HSR, Public Health and ELSI research meet. Montreal Canada, July 7, 2008.
75. Pharmacogenetic testing and warfarin dosing; Evidence-based evaluation of genetic tests in a public health context; and A review of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) program (3 talks). Sarah Lawrence College, Master's program for Genetic Counselors, Yonkers, New York, September 24, 2008.
76. Evidence-based evaluation of genetic tests in a public health context. Grand Rounds, Massachusetts General Hospital, Boston, Massachusetts, November 18, 2008
77. Designing clinical studies to validate fetal nucleic acid based tests or Down syndrome. American College of Medical Genetics - Industry supported symposia. ACMG Annual meeting, Tampa, Florida, March 26, 2009.
78. Prenatal screening for Down syndrome: Internal QC/QA, external proficiency testing and potential improvement. Sino-US Prenatal screening and diagnosis technology symposium. Beijing, China, June 19, 2010.
79. Prenatal screening for Down syndrome. Beckman Coulter Special Interest Group. Beijing, China, June 20, 2010.
80. Prenatal Genetic Screening. American College of Obstetricians and Gynecologists, District IX, Sacramento, California August 8, 2009.
81. Selected factors affecting screening markers, Repeated measures in Down syndrome screening, and Massively parallel sequencing and Down syndrome (3 talks). Emerging issues in prenatal screening. National Society of Genetic Counselors Annual meeting, 2010, Dallas Texas, October 15, 2010.
82. Consultant to the Evaluation of Genomic Applications in Practice and Prevention and (EGAPP) Working Group. Presented between 2004 and 2010:
 - Does the use of cardiogenomic profiling lead to improved outcome for the patient/consumer, or is it useful in medical or personal decision-making?
 - Genomic panels and the risk of cardiovascular disease: the story of 9p21.
 - Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
 - DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.
 - Does the identification of FVL mutations in adults with a personal history of venous thromboembolism lead to improved clinical outcomes?

83. Short Course, Essentials of Prenatal Screening. Annual presentations, 1985-2010. Presented the following at the 2010 course, March 19-22, 2010:

- Reference data and distributions for AFP
- Other factors that affect ONTD screening
- Combining markers into a single risk estimate - practical considerations
- Ultrasound and open neural tube defects
- First trimester markers for Down syndrome
- The first trimester screening experience
- Sequential, contingent, and serum integrated with repeated measures
- Interpreting results for trisomy 18
- Testing based on fetal RNA/DNA

GRANTS/CONSULTING:

1. Grant Title: Combining Maternal Age and Alpha-fetoprotein for Down Syndrome Screening: An Eight Center Collaborative Study
Funding Agency: New England Regional Genetics Group
Funding Amount: \$30,000
Dates: 12/1/86-11/31/87
PI: Glenn E. Palomaki, BS
2. Grant Title: Developing Processes for Evaluating DNA Tests
Funding Agency: Centers for Disease Control and Prevention
Funding Amount: \$766,134
Dates: 9/30/00-9/29/04
PI: James E. Haddow, M.D.
Principal Scientist: Glenn E. Palomaki, BS
3. Grant Title: Feasibility of Prenatal Screening for SLO Syndrome
Funding Agency: National Institute of Child Health and Human Development, NIH
Funding Amount: \$4,392,769
Dates: 4/1/00-3/31/05
PI: James E. Haddow, M.D.
Principal Scientist: Glenn E. Palomaki, BS
4. Contract Title: Hyperglycosolated hCG and Down syndrome
Funding Agency: Quest Diagnostics, Inc
Funding Amount: \$25,000
Dates: 11/1/04-10/31/06
Co-PI: Glenn E. Palomaki, BS
5. Contract Title: Consultant for the "Evaluation of Genomic Applications in Practice and Prevention Evidence (EGAPP) Program
Funding Agency: Centers for Disease Control and Prevention via McKing Consulting
Funding Amount: \$190,166
Dates: 8/15/06-8/31/2011
PI: Glenn E. Palomaki, BS

6. Grant Title: Rapid ACCE Review: Pharmacogenetic Testing & Coumadin/Warfarin Treatment
Funding Agency: American College of Medical Genetics Foundation
Funding Amount: \$18,000
Dates: 4/1/2006 - 8/30/2006
Co-PI: Glenn E. Palomaki, BS
Co-PI: Monica McClain, PhD
7. Grant Title: Estimating first trimester Combined Screening Performance for Down syndrome in Dried Blood Spots versus Fresh Sera Funding Agency: American College of Medical Genetics Foundation
Funding Amount: \$5,000
Dates: 2/1/2006-1/31/2007
PI: Glenn E. Palomaki, BS
8. Grant Title: Genetic Test Quality Initiative: Impact of Factor V and Prothrombin Genotyping and Recurrent Fetal Loss.
Funding Agency: Johns Hopkins University
Funding Amount: \$28,414
Dates: 4/1/09-9/30/09
Co-PI: Glenn E. Palomaki, BS
Co-PI: Linda Bradley, PhD
9. Contract Title: Consultant for the "Evaluation of Genomic Applications in Practice and Prevention Evidence (EGAPP) Program
Funding Agency: CDC, National Office of Public Health Genomics
Funding Amount: \$6,600
Dates: 4/1/09-9/30/09
PI: Glenn E. Palomaki, BS
10. Contract Title: A Laboratory Developed Test for the Detection of Down Syndrome in Early Pregnancy
Funding Agency: Sequenom, Inc
Funding Amount: \$4,493,901
Dates: 4/1/09-2/29/2012
Co-PI: Glenn E. Palomaki, PhD
Co-PI: Jack A. Canick, PhD
11. Contract Title: First trimester proficiency testing for Down syndrome
Funding Agency: College of American Pathologists
Funding Amount: \$31,500
Dates: 3/1/2011-2/29/2012
PI: Glenn E. Palomaki, PhD